The Wrong Inhaler for Ten Years: Stepping a 63-Year-Old Woman With COPD From an Inhaled Steroid Combination to Dual Long-Acting Bronchodilator Therapy
[Student Name]
University of Phoenix
NSG/522: Advanced Pharmacology
Week 3 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. No real patient is described.
A composite 63-year-old retired school bus driver with chronic obstructive pulmonary disease (COPD) came to a new nurse practitioner for a routine visit. She quit smoking five years ago after 40 pack-years. For ten years she had used fluticasone and salmeterol twice daily, prescribed when she was first diagnosed, plus albuterol as needed about once a day. She reported breathlessness when walking up a slight hill, a modified Medical Research Council dyspnea score of 2 and a COPD Assessment Test score of 18. She had one moderate exacerbation treated with prednisone last year and was hospitalized for pneumonia 18 months ago. Spirometry showed a post-bronchodilator FEV1 of 58% of predicted, and her blood eosinophil count was 150 cells per microliter. She had faithfully used an inhaler for a decade that exposed her to its main risk while leaving out the drug class most likely to help her breathe. This paper explains the pharmacology behind changing her regimen.
The Three Drug Classes
Long-acting beta-2 agonists (LABAs), such as salmeterol, formoterol and vilanterol, bind beta-2 adrenergic receptors on airway smooth muscle. Receptor activation stimulates adenylyl cyclase through a stimulatory G protein, raising cyclic adenosine monophosphate, which activates protein kinase A and relaxes smooth muscle, producing bronchodilation lasting 12 to 24 hours.
Long-acting muscarinic antagonists (LAMAs), such as tiotropium, umeclidinium and glycopyrronium, block muscarinic M3 receptors on airway smooth muscle and glands. In COPD, vagal cholinergic tone is a major and reversible contributor to airway narrowing, so blocking acetylcholine at M3 receptors relaxes smooth muscle and reduces mucus secretion. Because beta agonists and muscarinic antagonists act on different pathways that converge on smooth muscle tone, combining them produces additive bronchodilation.
Inhaled corticosteroids (ICSs), such as fluticasone and budesonide, bind intracellular glucocorticoid receptors and change gene transcription, suppressing inflammatory genes. In asthma, where inflammation is typically eosinophilic and steroid-responsive, they are the foundation of therapy. In COPD, inflammation is more often neutrophilic and relatively steroid-resistant, so ICS benefit is concentrated in patients with eosinophilic inflammation and frequent exacerbations.
Classifying Her With GOLD
The GOLD assessment combines airflow limitation, symptoms and exacerbation history. Her FEV1 of 58% of predicted places her in spirometric grade 2. For treatment, the current framework groups patients by exacerbations and symptoms: those with two or more moderate exacerbations or one or more leading to hospitalization in the past year are in group E, while those with fewer exacerbations are divided by symptom burden (Agusti et al., 2023). With one moderate exacerbation and no exacerbation hospitalization in the past year, and a symptom score of 18, she is in group B. For group B, the recommended initial therapy is a LABA plus LAMA combination, preferably in a single inhaler (Agusti et al., 2023). Her pneumonia 18 months ago was not an exacerbation of COPD, and it is relevant for a different reason.
Weighing the Inhaled Corticosteroid
Her current regimen contains a LABA but no LAMA, and it contains an ICS she may not need. ICSs increase the risk of pneumonia in COPD. Kew and Seniukovich (2014), in a Cochrane review, found that both fluticasone and budesonide increased the risk of serious pneumonia requiring hospitalization in people with COPD, without a significant effect on mortality. Her prior pneumonia hospitalization makes this risk concrete.
Evidence also shows when ICSs help. Lipson et al. (2018), in the IMPACT trial of patients with symptomatic COPD and a history of exacerbations, found that single-inhaler triple therapy with an ICS, LAMA and LABA reduced moderate or severe exacerbations compared with dual therapy, with greater benefit at higher blood eosinophil counts, and also found more pneumonia among patients receiving ICS-containing regimens. GOLD therefore recommends considering ICS mainly for patients with frequent exacerbations, especially when blood eosinophils are 300 cells per microliter or higher, and suggests that ICS is unlikely to help when eosinophils are below 100 (Agusti et al., 2023). With one moderate exacerbation and eosinophils of 150, she does not meet the threshold where benefit clearly outweighs harm.
The Change and How It Was Made
The nurse practitioner changed her to a once-daily LAMA and LABA combination in a single inhaler, umeclidinium and vilanterol, stopping the fluticasone and salmeterol, with albuterol continued as needed. Withdrawing the ICS in a patient without frequent exacerbations is supported by guidance, with monitoring for any increase in exacerbations. The once-daily device also simplified her routine from two inhalations a day to one.
Adverse effects were reviewed. LAMAs can cause dry mouth and, rarely, urinary retention or worsening of narrow-angle glaucoma; she had neither condition. LABAs can cause tremor, palpitations and hypokalemia at high doses. Oral candidiasis and hoarseness, which she had experienced on the ICS, were expected to resolve.
Device and Technique
An inhaled drug only works if it reaches the airways. The nurse practitioner watched her use the new dry powder inhaler and checked her peak inspiratory flow with a handheld meter, since dry powder devices need a fast, deep inhalation to disperse the powder. Her flow was adequate. She was taught to exhale fully away from the device, seal her lips, inhale quickly and deeply, hold her breath for several seconds and use the inhaler at the same time each day. If her inspiratory flow had been low, a soft mist or metered-dose inhaler with a spacer would have been a better choice.
Beyond the Inhaler
Pharmacotherapy is one part of COPD care. She was referred to pulmonary rehabilitation, which improves breathlessness and exercise capacity more than any change in inhaler, and was offered the updated pneumococcal, influenza, COVID-19 and respiratory syncytial virus vaccines recommended for her age and condition. A written action plan explained when to use albuterol, when to call and when to seek emergency care.
Cost and Access
Cost shapes adherence as much as pharmacology does. Single-inhaler LAMA and LABA combinations are brand-name products with substantial copayments for some Medicare beneficiaries, and a patient who cannot afford an inhaler will skip doses or stop it. The nurse practitioner checked the patient's Part D formulary, chose the combination on its preferred tier and told her about the manufacturer's assistance program in case her costs rose later in the year. If no combination product were affordable, separate LAMA and LABA inhalers or a generic option would be considered, accepting a more complex routine to keep both drug classes in her regimen.
Monitoring
At a follow-up visit in six weeks, the nurse practitioner will repeat the COPD Assessment Test, review albuterol use and inhaler technique and ask about any exacerbations. If she has two or more moderate exacerbations in the coming year, or her eosinophils rise to 300 or more, adding an ICS back as triple therapy would be reconsidered.
Conclusion
A ten-year-old prescription gave this woman an inhaled corticosteroid she likely did not need and omitted a long-acting muscarinic antagonist that could improve her breathing. Understanding how each drug class acts, classifying her with the GOLD framework and weighing the pneumonia risk of ICS against its modest benefit at her eosinophil level led to a once-daily LAMA and LABA inhaler, with attention to device technique, rehabilitation, vaccination and a plan for reassessment.
References
Agusti, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., Bourbeau, J., Han, M. K., Martinez, F. J., Montes de Oca, M., Mortimer, K., Papi, A., Pavord, I., Roche, N., Salvi, S., Sin, D. D., Singh, D., Stockley, R., Lopez Varela, M. V., ... Vogelmeier, C. F. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. European Respiratory Journal, 61(4), Article 2300239. https://doi.org/10.1183/13993003.00239-2023
Kew, K. M., & Seniukovich, A. (2014). Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, Article CD010115. https://doi.org/10.1002/14651858.CD010115.pub2
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Singh, D., Tabberer, M., Wise, R. A., & Pascoe, S. J. (2018). Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine, 378(18), 1671-1680. https://doi.org/10.1056/NEJMoa1713901
How this NSG 522 Week 3 example is structured
The University of Phoenix library guide for NSG/522 lists Week 3 as Respiratory, Cardiovascular, and Hematologic Medications. The paper treats inhaler choice as a pharmacology decision, not a formulary habit: it explains how each class acts at its receptor, uses the current classification to decide which classes fit the patient, weighs benefit and harm for the inhaled corticosteroid and closes with device technique, since an inhaled drug only works if it reaches the airways. Students search this week as NSG 522 Week 3, NSG522 Wk 3 or NSG/522 Wk 3; all three are the same assignment.
NSG/522 Week 3 questions, answered
What does NSG/522 Week 3 usually ask for?
The library guide for NSG/522 lists Week 3 as respiratory, cardiovascular and hematologic medications. Many sections ask for a paper or case analysis on selecting and managing drugs from one of these classes, including mechanism, evidence, adverse effects and patient teaching.
When is an inhaled corticosteroid indicated in COPD?
Current GOLD guidance reserves inhaled corticosteroids mainly for patients with frequent exacerbations and higher blood eosinophil counts, usually added to dual bronchodilator therapy. They are not recommended as the only long-term add-on for patients without exacerbation risk because they increase pneumonia risk.
Why does inhaler technique matter so much?
Because the dose that reaches the lungs depends on how the device is used. Many patients use inhalers incorrectly, and a dry powder inhaler needs a fast, strong inhalation that some older adults cannot generate. Checking technique is part of prescribing.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.